PPA
ATXI

Parametric Portfolio Associates’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Parametric Portfolio Associates’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9
Closed -$26K – 3675
2021
Q2 		$26K Sell
9
-14
-61% -$69.1K ﹤0.01% 3555
2021
Q1 		$157K Sell
23
-2
-8% -$13.7K ﹤0.01% 3918
2020
Q4 		$165K Buy
+25
New +$131K ﹤0.01% 3817

Other funds holding ATXI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Parametric Portfolio Associates's ATXI Position: Q3 2021 in Review

Parametric Portfolio Associates sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q3 2021, closing a stake of 9 shares — an estimated $26K sold.

Parametric Portfolio Associates first reported a position in ATXI in Q4 2020 and held it in 3 quarters. The position peaked at $165K in Q4 2020. 17 funds tracked by Wall St. Rank hold ATXI as of Q3 2021.

  • Parametric Portfolio Associates reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 9 Avenue Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $26K.
  • Parametric Portfolio Associates first reported a position in Avenue Therapeutics, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Parametric Portfolio Associates's Avenue Therapeutics, Inc. Common Stock position peaked at $165K in Q4 2020.
  • 17 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Parametric Portfolio Associates's 13F filing for Q3 2021, filed 15 Nov 2021.